Rheumatology Advance Access originally published online on May 28, 2009
Rheumatology 2009 48(8):906-910; doi:10.1093/rheumatology/kep129
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Missed opportunities in the treatment of elderly patients with rheumatoid arthritis
1Department of Rheumatology, Radboud University Nijmegen Medical Centre and 2Department of Rheumatology, Sint Maartenskliniek, Nijmegen, The Netherlands.
Correspondence to: Beata J. Radovits, Department of Rheumatology, Radboud University Nijmegen Medical Centre, P.O. Box 9101, Hp 470, 6500 HB Nijmegen, The Netherlands. E-mail: B.Radovits{at}reuma.umcn.nl; bradovits{at}hotmail.com
| Abstract |
|---|
Objective. To investigate whether there is a difference in waiting time between indication and start of anti-TNF-
therapy in younger and older RA patients.
Methods. The study was carried out in the Nijmegen inception cohort of early RA. All patients meeting indications for anti-TNF-
therapy according to the Dutch reimbursement criteria were included in the analysis. Time from indication to start of anti-TNF-
therapy or censoring was calculated in all patients. Multivariable Cox regression analysis was used to investigate the influence of age at indication on the time to commencement of anti-TNF-
treatment. Hazard ratios were calculated for groups in age quartiles. The model was corrected for 28-joint disease activity score (DAS28), disease duration, gender, the Charlson comorbidity index and episodes of serious illnesses between indication and anti-TNF-
therapy or censoring.
Results. From the 487 eligible patients, 215 patients started anti-TNF-
treatment during their follow-up (44%). Age significantly influenced the time to receiving anti-TNF-
after first indication, adjusting for confounders (HR = 0.975/year, P < 0.001). The same analysis using age quartiles showed that the younger age groups had a higher chance of receiving anti-TNF-
treatment within an equal period of time than older patients [HR 2.67 (95% CI 1.64, 4.35); 2.30 (1.43, 3.71); 1.79 (1.14, 2.81) with increasing age; the eldest group as reference]. The eldest patients had significantly higher DAS28 values prior to anti-TNF-
treatment than younger patients.
Conclusion. Elderly RA patients were less likely to receive anti-TNF-
treatment within an equal period of time compared with younger patients, taking disease activity, disease duration and comorbidities into account.
KEY WORDS: Rheumatoid arthritis, Decision making, Elderly, Anti-TNF-
treatment, Indication
Submitted 18 November 2008;
revised version accepted 21 April 2009.
![]()
CiteULike
Connotea
Del.icio.us What's this?